Literature DB >> 26997932

Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis.

Dimitri Poddighe1, Valeria Brazzelli2, Amelia Licari3, Gian Luigi Marseglia3.   

Abstract

Atopic dermatitis is considered an important risk factor for chronic hand dermatitis, which can be seen in children too. Pimecrolimus cream 1% is approved to treat atopic dermatitis in children aged 2 years or older. In adults, this drug has been used for some clinical indications other than atopic dermatitis, such as chronic hand dermatitis. Here, we describe an adverse drug reaction in a 2-year-old child affected with atopic dermatitis, who was treated with topical pimecrolimus in order to ameliorate her concomitant hand dermatitis. The use of topical pimecrolimus led to a previously undescribed hand pustular dermatosis, being consistent with a form of pustular leukocytoclastic vasculitis, which required the permanent discontinuation of topical pimecrolimus.

Entities:  

Keywords:  Elidel cream; adverse drug effect; atopic dermatitis; pediatric; pimecrolimus; pustular dermatitis

Year:  2016        PMID: 26997932      PMCID: PMC4778701          DOI: 10.5863/1551-6776-21.1.81

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  18 in total

1.  Clinical evaluation of atopic hand-foot dermatitis.

Authors:  H J Lee; S J Ha; W K Ahn; D Kim; Y M Park; D G Byun; J W Kim
Journal:  Pediatr Dermatol       Date:  2001 Mar-Apr       Impact factor: 1.588

2.  Children with Atopic Dermatitis Should Always be Patch-tested if They Have Hand or Foot Dermatitis.

Authors:  Marléne Isaksson; Sanna Olhardt; Jeanette Rådehed; Åke Svensson
Journal:  Acta Derm Venereol       Date:  2015-05       Impact factor: 4.437

Review 3.  New insights into pustular dermatoses in pediatric patients.

Authors:  Claudia J Posso-De Los Rios; Elena Pope
Journal:  J Am Acad Dermatol       Date:  2013-12-31       Impact factor: 11.527

4.  Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants.

Authors:  Vincent C Ho; Aditya Gupta; Roland Kaufmann; Gail Todd; Francisco Vanaclocha; Roberto Takaoka; Regina Fölster-Holst; Paul Potter; Katherine Marshall; Mark Thurston; Christopher Bush; Robert Cherill
Journal:  J Pediatr       Date:  2003-02       Impact factor: 4.406

5.  Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial.

Authors:  Maria Hordinsky; Alan Fleischer; Jason K Rivers; Yves Poulin; Donald Belsito; Thomas Hultsch
Journal:  Dermatology       Date:  2010-06-08       Impact factor: 5.366

Review 6.  Patch tests in children with suspected allergic contact dermatitis: a prospective study and review of the literature.

Authors:  Flora B de Waard-van der Spek; Arnold P Oranje
Journal:  Dermatology       Date:  2008-10-22       Impact factor: 5.366

7.  Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis.

Authors:  Donald V Belsito; Joseph F Fowler; James G Marks; David M Pariser; Jon Hanifin; Ida Alzira Gomes Duarte; Mario C Pires; Ponciano D Cruz; Richard G B Langley; Premal Patel; Christopher Bush; Mark Thurston; Michael Graeber; Robert Cherill
Journal:  Cutis       Date:  2004-01

Review 8.  Classification of atopic hand eczema and the filaggrin mutations.

Authors:  Charlotte Giwercman; Anne Lerbaek; Hans Bisgaard; Torkil Menné
Journal:  Contact Dermatitis       Date:  2008-11       Impact factor: 6.600

Review 9.  Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.

Authors:  Thomas Luger; Linda De Raeve; Carlo Gelmetti; Talia Kakourou; Alexandra Katsarou; Julien Lambert; Marie-Anne Morren; Arnold Oranje; Mireille Ruer; Server Serdaroglu; Antonio Torrelo; Thomas Werfel
Journal:  Eur J Dermatol       Date:  2013 Nov-Dec       Impact factor: 3.328

Review 10.  Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.

Authors:  Thomas Luger; Mark Boguniewicz; Warner Carr; Michael Cork; Mette Deleuran; Lawrence Eichenfield; Philippe Eigenmann; Regina Fölster-Holst; Carlo Gelmetti; Harald Gollnick; Eckard Hamelmann; Adelaide A Hebert; Antonella Muraro; Arnold P Oranje; Amy S Paller; Carle Paul; Luis Puig; Johannes Ring; Elaine Siegfried; Jonathan M Spergel; Georg Stingl; Alain Taieb; Antonio Torrelo; Thomas Werfel; Ulrich Wahn
Journal:  Pediatr Allergy Immunol       Date:  2015-04-13       Impact factor: 6.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.